Doximity (DOCS) Stock Forecast & Price Target

$40.16

+0.72 (+1.83%)

(As of 09/17/2024 ET)

Doximity - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 14 Analyst Ratings

Based on 14 Wall Street analysts who have issued ratings for Doximity in the last 12 months, the stock has a consensus rating of "Hold." Out of the 14 analysts, 2 have given a sell rating, 8 have given a hold rating, and 4 have given a buy rating for DOCS.

Consensus Price Target

$32.42
-19.28% Downside

High Forecast	$45.00
Average Forecast	$32.42
Low Forecast	$19.00

According to the 14 analysts' twelve-month price targets for Doximity, the average price target is $32.42. The highest price target for DOCS is $45.00, while the lowest price target for DOCS is $19.00. The average price target represents a forecasted downside of -19.28% from the current price of $40.16.

Type	Current Forecast 9/18/23 to 9/17/24	1 Month Ago 8/19/23 to 8/18/24	3 Months Ago 6/20/23 to 6/19/24	1 Year Ago 9/18/22 to 9/18/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	11 Hold rating(s)	6 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$32.42	$30.18	$28.73	$29.50
Forecasted Upside	-19.28% Downside	4.42% Upside	8.57% Upside	2.34% Upside

Big News: How the Upcoming Rate Cut and Elon Musk’s AI Could Transform Your Investments (Ad)

The Federal Reserve is almost certainly about to cut interest rates, and history tells us that stocks often rally after such moves. In fact, based on my calculations, in seven out of nine rate-cut cycles since 1981, stocks have surged, delivering an average of 36.3% returns over two years. But that's not all... This time, there's another massive trigger on the horizon – Elon Musk's groundbreaking AI technology.

Click here to learn how you can take advantage of these two monumental shifts right now.

DOCS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DOCS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Doximity Stock vs. The Competition

Type	Doximity	Medical Companies	S&P 500
Consensus Rating Score	2.14	2.77	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-19.28% Downside	1,004.47% Upside	7.67% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/17/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$41.00 ➝ $45.00	+14.10%
8/20/2024	Canaccord Genuity Group 1 of 5 stars		Boost Target	Buy ➝ Buy	$37.00 ➝ $40.00	+11.08%
8/19/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Neutral ➝ Neutral	$27.00 ➝ $30.00	-16.11%
8/14/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Hold	$31.00 ➝ $35.00	-0.26%
8/9/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	In-Line ➝ In-Line	$29.00 ➝ $34.00	+1.19%
8/9/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$29.00 ➝ $32.00	-5.58%
Is A Starlink IPO Coming In 2024? (Ad) He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO. Click here now for the urgent details on this hidden play.
8/9/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $35.00	+0.84%
8/9/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underweight ➝ Underweight	$25.00 ➝ $26.00	+1.29%
8/9/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Berg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$38.00	+48.03%
7/18/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Berenshteyn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$27.00 ➝ $19.00	-34.46%
5/17/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
2/26/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$32.00	+13.11%
11/10/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$21.00 ➝ $23.00	-3.48%
8/9/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$40.00 ➝ $30.00	+18.58%
8/9/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
10/13/2022	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:45 PM ET.

DOCS Forecast - Frequently Asked Questions

What is Doximity's forecast for 2024?: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Doximity is $32.42, with a high forecast of $45.00 and a low forecast of $19.00.
Should I buy or sell Doximity stock right now?: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Doximity in the last twelve months. There are currently 2 sell ratings, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DOCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DOCS, but not buy additional shares or sell existing shares.
Does Doximity's stock price have much upside?: According to analysts, Doximity's stock has a predicted upside of 2.11% based on their 12-month stock forecasts.
Has Doximity been upgraded or downgraded by Wall Street analysts recently?: Over the previous 90 days, Doximity's stock had 1 upgrade and 1 downgrade by analysts.
What analysts cover Doximity?: Doximity has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Robert W. Baird, Truist Financial, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like Doximity more than its competitors?: Analysts like Doximity less than other "medical" companies. The consensus rating for Doximity is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DOCS compares to other companies.